Diabetes mellitus and Alzheimer’s disease

Main Article Content

N.V. Pashkovska
V.I. Pankiv
N.V. Grinko
O.V. Pashkovska


The article reviews modern information on epidemiology and risk factors for Alzheimer’s disease in diabetes mellitus. The literature data on the main pathogenetic links of the development of neurodegenerative disorders in diabetic patients, as well as the mechanisms of mutual burden are analyzed. The article deals with the results of clinical studies on the possibilities of pathogenetic correction of cognitive disorders in Alzheimer’s disease, which runs on the background of diabetes mellitus.

Article Details

How to Cite
Pashkovska, N., V. Pankiv, N. Grinko, and O. Pashkovska. “Diabetes Mellitus and Alzheimer’s Disease”. INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine), vol. 15, no. 3, July 2019, pp. 188-95, doi:10.22141/2224-0721.15.3.2019.172103.
Leading Article


World Health Organization. Dementia. http://www.who.int/mediacentre/factsheets/fs362/en/. Available from: May 14, 2019.

Riederer P, Korczyn AD, Ali SS, et al. The diabetic brain and cognition. J Neural Transm (Vienna). 2017 Nov;124(11):1431-1454. doi: 10.1007/s00702-017-1763-2.

Gudala K, Bansal D, Schifano F, Bhansali A. Diabetes mellitus and risk of dementia: A meta-analysis of prospective observational studies. J Diabetes Investig. 2013 Nov 27;4(6):640-50. doi: 10.1111/jdi.12087.

Ott A, Stolk RP, van Harskamp F, Pols HA, Hofman A, Breteler MM. Diabetes mellitus and the risk of dementia: The Rotterdam Study. Neurology. 1999;53(9):1937-42. doi: 10.1212/wnl.53.9.1937.

Cheng G, Huang C, Deng H, Wang H. Diabetes as a risk factor for dementia and mild cognitive impairment: a meta-analysis of longitudinal studies. Intern Med J. 2012 May;42(5):484-91. doi: 10.1111/j.1445-5994.2012.02758.x.

Samaras K, Sachdev PS. Diabetes and the elderly brain: sweet memories? Ther Adv Endocrinol Metab. 2012 Dec;3(6):189-96. doi: 10.1177/2042018812469645.

Kotov AS, Yeliseyev YV, Semenova EI. Alzheimer’s disease: from theory to practice. Meditsinskii sovet. 2015;(18):41-45. (in Russian).

Lane CA, Hardy J, Schott JM. Alzheimer’s disease. Eur J Neurol. 2018 Jan;25(1):59-70. doi: 10.1111/ene.13439.

Bermejo-Pareja F1, Benito-León J, Vega S, Medrano MJ, Román GC; Neurological Disorders in Central Spain (NEDICES) Study Group. Incidence and subtypes of dementia in three elderly populations of central Spain. J Neurol Sci. 2008 Jan 15;264(1-2):63-72. doi: 10.1016/j.jns.2007.07.021.

Dodd GT, Tiganis T. Insulin action in the brain: Roles in energy and glucose homeostasis. J Neuroendocrinol. 2017 Oct;29(10). doi: 10.1111/jne.12513.

Costello DA, Claret M, Al-Qassab Hб, et al. Brain deletion of insulin receptor substrate 2 disrupts hippocampal synaptic plasticity and metaplasticity. PLoS One. 2012;7(2):e31124. doi: 10.1371/journal.pone.0031124.

Crane PK, Walker R, Hubbard RA, et al. Glucose levels and risk of dementia. N Engl J Med. 2013 Aug 8;369(6):540-8. doi: 10.1056/NEJMoa1215740.

Abbatecola AM, Rizzo MR, Barbieri M, et al. Postprandial plasma glucose excursions and cognitive functioning in aged type 2 diabetics. Neurology. 2006 Jul 25;67(2):235-40. doi: 10.1212/01.wnl.0000224760.22802.e8.

Shukla V, Shakya AK, Perez-Pinzon MA, Dave KR. Cerebral ischemic damage in diabetes: an inflammatory perspective. J Neuroinflammation. 2017 Jan 23;14(1):21. doi: 10.1186/s12974-016-0774-5.

Auer RN. Hypoglycemic brain damage. Metab Brain Dis. 2004 Dec;19(3-4):169-75.

Yun JS, Ko SH. Risk Factors and adverse outcomes of severe hypoglycemia in type 2 diabetes mellitus. Diabetes Metab J. 2016 Dec;40(6):423-432. doi: 10.4093/dmj.2016.40.6.423.

Feinkohl I, Aung PP, Keller M, et al. Severe hypoglycemia and cognitive decline in older people with type 2 diabetes: the Edinburgh type 2 diabetes study. Diabetes Care. 2014 Feb;37(2):507-15. doi: 10.2337/dc13-1384.

De Galan BE, Zoungas S, Chalmers J, et al. Cognitive function and risks of cardiovascular disease and hypoglycaemia in patients with type 2 diabetes: the Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation (ADVANCE) trial. Diabetes Care. 2014 Feb;37(2):507-15. doi: 10.2337/dc13-1384.

Laws SM, Gaskin S, Woodfield A, et al. Insulin resistance is associated with reductions in specific cognitive domains and increases in CSF tau in cognitively normal adults. Sci Rep. 2017 Aug 29;7(1):9766. doi: 10.1038/s41598-017-09577-4.

Bernstein LH. Brain and Cognition. Available from: https://pharmaceuticalintelligence.com/2015/10/14/brain-and-cognition/. Accessed: October 14, 2015.

De la Monte SM, Tong M. Brain metabolic dysfunction at the core of Alzheimer’s disease. Biochem Pharmacol. 2014 Apr 15;88(4):548-59. doi: 10.1016/j.bcp.2013.12.012.

Derakhshan F, Toth C. Insulin and the brain. Curr Diabetes Rev. 2013 Mar 1;9(2):102-16.

Shpakov A, Chistyakova O, Derkach K, Bondareva V. Hormonal signaling systems of the brain in diabetes mellitus. In: Chang RCC, editor. Neurodegenerative Diseases. Rijeka, Croatia: Intech Open Access Publisher; 2011. 349-386 pp. doi: 10.5772/28930.

Kleinridders A, Ferris HA, Cai W, Kahn CR. Insulin action in brain regulates systemic metabolism and brain function. diabetes. 2014 Jul;63(7):2232-43. doi: 10.2337/db14-0568.

Leszek J, Trypka E, Tarasov VV, Ashraf GM, Aliev G.Type 3 Diabetes Mellitus: A Novel Implication of Alzheimers Disease. Curr Top Med Chem. 2017;17(12):1331-1335. doi: 10.2174/1568026617666170103163403.

Pivovarova O, Höhn A, Grune T, Pfeiffer AF, Rudovich N. Insulin-degrading enzyme: new therapeutic target for diabetes and Alzheimer’s disease? Ann Med. 2016 Dec;48(8):614-624. doi: 10.1080/07853890.2016.1197416.

Roostaei T, Nazeri A, Felsky D, et al. Genome-wide interaction study of brain beta-amyloid burden and cognitive impairment in Alzheimer’s disease. Mol Psychiatry. 2017 Feb;22(2):287-295. doi: 10.1038/mp.2016.35.

Zhu H, Xue X, Wang E, et al. Amylin receptor ligands reduce the pathological cascade of Alzheimer’s disease. Neuropharmacology. 2017 Jun;119:170-181. doi: 10.1016/j.neuropharm.2017.03.030.

Jackson K, Barisone GA, Diaz E, Jin LW, DeCarli C, Despa F. Amylin deposition in the brain: A second amyloid in Alzheimer disease? Ann Neurol. 2013 Oct;74(4):517-26. doi: 10.1002/ana.23956.

Zhu H, Stern R, Tao Q, et al. An amylin analog used as a challenge test for Alzheimer’s disease. Alzheimers Dement (NY). 2017 Jan;3(1):33-43. doi: 10.1016/j.trci.2016.12.002.

Williamson JD, Launer LJ, Bryan RN, et al. Cognitive function and brain structure in persons with type 2 diabetes mellitus after intensive lowering of blood pressure and lipid levels: a randomized clinical trial. JAMA Intern Med. 2014 Mar;174(3):324-33. doi: 10.1001/jamainternmed.2013.13656.

Wu JH, Haan MN, Liang J, Ghosh D, Gonzalez HM, Herman WH. Impact of antidiabetic medications on physical and cognitive functioning of older Mexican Americans with diabetes mellitus: a population-based cohort study. Ann Epidemiol. 2003 May;13(5):369-76.

Weinstock RS, Teresi J, Goland R, et al. Glycemic Control and Health Disparities in Older Ethnically Diverse Underserved Adults with Diabetes: Five-year results from the Informatics for Diabetes Education and Telemedicine (IDEATel) study. Diabetes Care. 2011 Feb;34(2):274-9. doi: 10.2337/dc10-1346.

Launer LJ, Miller ME, Williamson JD, et al. Effects of randomization to intensive glucose lowering on brain structure and function in type 2 diabetes ACCORD Memory in Diabetes Study. Lancet Neurol. 2011 Nov;10(11):969-77. doi: 10.1016/S1474-4422(11)70188-0.

Pashkovska NV. Cognitive impairment in patients with type 2 diabetes mellitus: the role of hypoglycemic therapy. Mìžnarodnij endokrinologìčnij žurnal. 2018;14(1):76-85. doi: 10.22141/2224-0721.14.1.2018.127097. (in Ukrainian).

Plastino M, Fava A, Pirritano D, et al. Effects of insulinic therapy on cognitive impairment in patients with Alzheimer’s disease and diabetes mellitus type 2. J Neurodegener Dis. 2013;2013:454253. doi: 10.1155/2013/454253.

Craft S, Baker LD, Montine TJ, et al. Intranasal Insulin Therapy for Alzheimer Disease and Amnestic Mild Cognitive Impairment. Arch Neurol. 2012 Jan;69(1):29-38. doi: 10.1001/archneurol.2011.233.

Wang YW, He SJ, Feng X, et al. Metformin: a review of its potential indications. Drug Des Devel Ther. 2017 Aug 22;11:2421-2429. doi: 10.2147/DDDT.S141675.

Markowicz-Рiasecka M, Sikora J, Szydłowska A, Skupień A, Mikiciuk-Оlasik E, Huttunen KM. Metformin - a Future Therapy for Neurodegenerative Diseases : Theme: Drug Discovery, Development and Delivery in Alzheimer's Disease Guest Editor: Davide Brambilla. Pharm Res. 2017 Dec;34(12):2614-2627. doi: 10.1007/s11095-017-2199-y.

Fatt M, Hsu K, He L, et al. Metformin Acts on Two Different Molecular Pathways to Enhance Adult Neural Precursor Proliferation/Self-Renewal and Differentiation. Stem Cell Reports. 2015 Dec 8;5(6):988-995. doi: 10.1016/j.stemcr.2015.10.014.

Ge XH, Zhu GJ, Geng DQ, et al. Metformin protects the brain against ischemia/reperfusion injury through PI3K/Akt1/ JNK3 signaling pathways in rats. Physiol Behav. 2017 Mar 1;170:115-123. doi: 10.1016/j.physbeh.2016.12.021.

Pintana H, Apaijai N, Pratchayasakul W, Chattipakorn N, Chattipakorn SC. Effects of metformin on learning and memory behaviors and brain mitochondrial functions in high fat diet induced insulin resistant rats. Life Sci. 2012 Oct 5;91(11-12):409-414. doi: 10.1016/j.lfs.2012.08.017.

Hettich MM, Matthes F, Ryan DP, et al. The Anti-Diabetic Drug Metformin Reduces BACE1 Protein Level by Interfering with the MID1 Complex. PLoS One. 2014 Jul 15;9(7):e102420. doi: 10.1371/journal.pone.0102420.

Bibi F, Ullah I, Kim MO, Naseer MI. Metformin attenuate PTZ-induced apoptotic neurodegeneration in human cortical neuronal cells. Pak J Med Sci. 2017 May-Jun;33(3):581-585. doi: 10.12669/pjms.333.11996.

Markowicz-Piasecka M, Sikora J, Mateusiak Ł, Mikiciuk-Olasik E, Huttunen KM. Metformin and Its Sulfonamide Prodrugs Inhibit Human Cholinesterase Activity. Oxid Med Cell Longev. 2017;2017:7303096. doi: 10.1155/2017/7303096.

Kuan YC, Huang KW, Lin CL, Hu CJ, Kao CH. Effects of metformin exposure on neurodegenerative diseases in elderly patients with type 2 diabetes mellitus. Prog Neuropsychopharmacol Biol Psychiatry. 2017 Oct 3;79(Pt B):77-83. doi: 10.1016/j.pnpbp.2017.06.002.

Koenig AM, Mechanic-Hamilton D, Xie SX, et al. Effects of the Insulin Sensitizer Metformin in Alzheimer Disease: Pilot Data from a Randomized Placebo-controlled Crossover Study. Alzheimer Dis Assoc Disord. 2017 Apr-Jun;31(2):107-113. doi: 10.1097/WAD.0000000000000202.

Imfeld P, Bodmer M, Jick SS, Meier CR. Metformin, other antidiabetic drugs, and risk of Alzheimer’s disease: a population-based case-control study. J Am Geriatr Soc. 2012 May;60(5):916-21. doi: 10.1111/j.1532-5415.2012.03916.x.

Moore EM, Mander AG, Ames D,et al. Increased Risk of Cognitive Impairment in Patients with Diabetes Is Associated with Metformin. Diabetes Care. 2013 Oct;36(10):2981-7. doi: 10.2337/dc13-0229.

Zherdeva NN. New page in metformin prescription. Praktykujuchyj likar. 2015;(1):65-67. (in Ukrainian).

Seaquist ER, Miller ME, Fonseca V, et al. Effect of thiazolidinediones and insulin on cognitive outcomes in ACCORD-MIND. J Diabetes Complications. 2013 Sep-Oct;27(5):485-91. doi: 10.1016/j.jdiacomp.2013.03.005.

Cheng C, Lin CH, Tsai YW, Tsai CJ, Chou PH, Lan TH. Type 2 diabetes and antidiabetic medications in relation to dementia diagnosis. J Gerontol A Biol Sci Med Sci. 2014 Oct;69(10):1299-305. doi: 10.1093/gerona/glu073.

Fu H, Xie W, Curtis B, Schuster D. Identifying factors associated with hypoglycemia-related hospitalizations among elderly patients with T2DM in the US: a novel approach using influential variable analysis. Curr Med Res Opin. 2014 Sep;30(9):1787-93. doi: 10.1185/03007995.2014.922944.

Orkaby AR, Cho K, Cormack J, Gagnon DR, Driver JA. Metformin vs sulfonylurea use and risk of dementia in US veterans aged 65 years with diabetes. Neurology. 2017 Oct 31;89(18):1877-1885. doi: 10.1212/WNL.0000000000004586.

Cai XS, Tan ZG, Li JJ, et al. Glucagon-Like Peptide-1 (GLP-1) Treatment Ameliorates Cognitive Impairment by Attenuating Arc Expression in Type 2 Diabetic Rats. Med Sci Monit. 2017 Sep 8;23:4334-4342. doi: 10.12659/msm.903252.

Li Y, Duffy KB, Ottinger MA, et al. GLP-1 Receptor Stimulation Reduces Amyloid-β Peptide Accumulation and Cytotoxicity in Cellular and Animal Models of Alzheimer’s Disease. J Alzheimers Dis. 2010;19(4):1205-19. doi: 10.3233/JAD-2010-1314.

Velmurugan K, Bouchard R, Mahaffey G, Pugazhenthi S. Neuroprotective actions of glucagon-like peptide-1 in differentiated human neuroprogenitor cells. J Neurochem. 2012 Dec;123(6):919-31. doi: 10.1111/jnc.12036.

Hansen HH, Fabricius K, Barkholt P, et al. Long-Term Treatment with Liraglutide, a Glucagon-Like Peptide-1 (GLP-1) Receptor Agonist, Has No Effect on β-Amyloid Plaque Load in Two Transgenic APP/PS1 Mouse Models of Alzheimer’s Disease. PLoS One. 2016 Jul 15;11(7):e0158205. doi: 10.1371/journal.pone.0158205.

Kosaraju J, Holsinger RM, Guo L, Tam KY. Linagliptin, a Dipeptidyl Peptidase-4 Inhibitor, Mitigates Cognitive Deficits and Pathology in the 3xTg-AD Mouse Model of Alzheimer’s Disease. Mol Neurobiol. 2017 Oct;54(8):6074-6084. doi: 10.1007/s12035-016-0125-7.

Jain S, Sharma B. Neuroprotective effect of selective DPP-4 inhibitor in experimental vascular dementia. Physiol Behav. 2015 Dec 1;152(Pt A):182-93. doi: 10.1016/j.physbeh.2015.09.007.

Lin B, Koibuchi N, Hasegawa Y, et al. Glycemic control with empagliflozin, a novel selective SGLT2 inhibitor, ameliorates cardiovascular injury and cognitive dysfunction in obese and type 2 diabetic mice. Cardiovasc Diabetol. 2014 Oct 26;13:148. doi: 10.1186/s12933-014-0148-1.

Rizvi SM, Shakil S, Biswas D, et al. Invokana (Canagliflozin) as a dual inhibitor of acetylcholinesterase and sodium glucose co-transporter 2: advancement in Alzheimer’s disease – diabetes type 2 linkage via an enzoinformatics study. CNS Neurol Disord Drug Targets. 2014 Apr;13(3):447-51.

Shaikh S, Rizvi SM, Shakil S, Riyaz S, Biswas D, Jahan R. Forxiga (dapagliflozin): Plausible role in the treatment of diabetes-associated neurological disorders. Biotechnol Appl Biochem. 2016 Jan-Feb;63(1):145-50. doi: 10.1002/bab.1319.

Qiu WQ. Amylin and its G-protein-coupled receptor: A probable pathological process and drug target for Alzheimer’s disease. Neuroscience. 2017 Jul 25;356:44-51. doi: 10.1016/j.neuroscience.

Zhang N, Yang S, Wang C, et al. Multiple target of hAmylin on rat primary hippocampal neurons. Neuropharmacology. 2017 Feb;113(Pt A):241-251. doi: 10.1016/j.neuropharm.

Most read articles by the same author(s)

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 > >>